Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04599972 · ClinicalTrials.gov registry record · Phase 3
An Evaluation of the Efficacy and Safety of CSF-1 in the Temporary Correction of Presbyopia (NEAR-2)
A Phase 3 study of Presbyopia, sponsored by Orasis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 304
- Enrollment target
- 18
- Study locations
NCT04599972 is a Phase 3 study of Presbyopia that has completed, run by Orasis Pharmaceuticals. The registered enrollment target is 304 participants, above the 263-participant average among 38 other Presbyopia trials with a reported enrollment target (16% higher). The trial reports 18 study locations across 11 states.
The verdict
NCT04599972, a Phase 3 study of Presbyopia, has completed, sponsored by Orasis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 304 participants
- Enrollment target
- 18
- Study locations
Study Summary
This is a 4-visit, multi-center, randomized, double-masked, vehicle-controlled study evaluating the safety and efficacy of CSF-1 in the temporary correction of presbyopia.
Conditions Studied
Interventions
- DRUG Vehicle
- DRUG CSF-1
Study Locations (18)
California
- Orasis Investigative Site - Garden Grove
- Orasis Investigative Site - Mission Hills
- Orasis Investigative Site - Newport Beach
- Orasis Investigative Site - Petaluma
Arizona
- Orasis Investigative Site - Chandler
- Orasis Investigative Site - Mesa
- Orasis Investigative Site - Phoenix
Texas
- Orasis Investigative Site - Cedar Park
- Orasis Investigative Site - San Antonio
Utah
- Orasis Investigative Site - Clinton
- Orasis Investigative Site - Draper
Colorado
- Orasis Investigative Site - Littleton
Connecticut
- Orasis Investigative Site - Danbury
Florida
- Orasis Investigative Site - Delray Beach
Illinois
- Orasis Investigative Site - Rock Island
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 304 participants |
| Start Date | 2020-10-26 |
| Est. Completion | 2022-01-28 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04599972
The ClinicalTrials.gov registry entry for NCT04599972 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 304 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 263-participant average among 38 other Presbyopia trials with a reported enrollment target (16% higher). The listed sponsor is Orasis Pharmaceuticals, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Presbyopia appearing as the primary indexed condition, and to 2 interventions - of which Vehicle is the first listed.
NCT04599972 reports 18 study locations spanning 11 distinct geographic areas - top geographies include California, Arizona, Texas.
Frequently Asked Questions
What is clinical trial NCT04599972 about?
NCT04599972 is a clinical study titled "An Evaluation of the Efficacy and Safety of CSF-1 in the Temporary Correction of Presbyopia (NEAR-2)". This is a 4-visit, multi-center, randomized, double-masked, vehicle-controlled study evaluating the safety and efficacy of CSF-1 in the temporary correction of presbyopia.
What is the current status of trial NCT04599972?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 304 participants. The study started on 2020-10-26. Estimated completion is 2022-01-28.
What conditions does trial NCT04599972 study?
This clinical trial studies the following conditions: Presbyopia.
What interventions are being tested in trial NCT04599972?
The interventions under investigation include: Vehicle (DRUG), CSF-1 (DRUG).
Who is sponsoring clinical trial NCT04599972?
This trial is sponsored by Orasis Pharmaceuticals, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04599972 being conducted?
This trial has 18 study locations across Arizona, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Presbyopia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase III Presbyopia Correction Using the VIS Opti-K™ System
RECRUITING · Phase 3
-
Safety & Efficacy of Pilocarpine Eye Solutions for Temporary Improvement of Near Vision in Presbyopic Adults
COMPLETED · Phase 3
-
Safety and Efficacy Study of BRIMOCHOL™ PF and Carbachol PF in Subjects With Emmetropic Phakic and Pseudophakic Presbyopia
COMPLETED · Phase 3
-
Safety & Efficacy of Pilocarpine Ophthalmic Spray for Temporary Improvement of Near Vision in Presbyopic Adults
COMPLETED · Phase 3
-
Phase 3 Safety Study for the Treatment of Presbyopia Subjects
COMPLETED · Phase 3
-
Post Market Clinical Evaluation of Clareon PanOptix Pro and Clareon PanOptix Pro Toric IOLs
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.